Biora Therapeutics, Inc.
BIOR · OTC
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $1 | $1 |
| % Growth | -89.9% | -41.3% | -37.8% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $1 | -$0 |
| % Margin | 100% | 65.4% | 100% | -13.4% |
| R&D Expenses | $6 | $8 | $7 | $6 |
| G&A Expenses | $0 | $0 | $0 | $8 |
| SG&A Expenses | $11 | $8 | $9 | $7 |
| Sales & Mktg Exp. | $0 | $0 | $0 | -$1 |
| Other Operating Expenses | $0 | -$0 | $0 | $0 |
| Operating Expenses | $16 | $16 | $16 | $13 |
| Operating Income | -$16 | -$16 | -$16 | -$13 |
| % Margin | -50,709.4% | -4,964.2% | -2,862.7% | -1,530.3% |
| Other Income/Exp. Net | -$6 | $22 | $11 | -$2 |
| Pre-Tax Income | -$22 | $6 | -$4 | -$16 |
| Tax Expense | -$0 | -$0 | $0 | -$0 |
| Net Income | -$18 | $6 | -$4 | -$15 |
| % Margin | -57,506.3% | 2,033% | -772.9% | -1,767.5% |
| EPS | -5.04 | -0 | -0.14 | -0.62 |
| % Growth | -5,039,900% | 99.9% | 77.4% | – |
| EPS Diluted | -5.04 | 0 | -0.14 | -0.62 |
| Weighted Avg Shares Out | 4 | 35,720 | 29 | 25 |
| Weighted Avg Shares Out Dil | 4 | 74,216 | 29 | 25 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $2 | $1 | $3 | $2 |
| Depreciation & Amortization | $4 | $0 | $0 | $0 |
| EBITDA | -$16 | $7 | -$1 | -$14 |
| % Margin | -50,709.4% | 2,270.1% | -236% | -1,579.1% |